📖 Peptide Protocol Guide

💉 General Injection Guidelines

Reconstitution: Use bacteriostatic water. Add slowly along the vial wall, don't shake.
Injection sites: Rotate between abdomen, thigh, and upper arm.
Needle size: 29-31 gauge insulin syringes for subcutaneous injections.
Timing: Most peptides are best taken on an empty stomach or before bed.

🌡️ Storage Guidelines

Lyophilized (Powder)

Store at -20°C for long-term. Stable at 2-8°C for weeks.

Reconstituted

Refrigerate at 2-8°C. Use within 14-28 days depending on peptide.

Jump to:

✨ Anti-Aging, Skin & Cellular Repair▼

Peptides and compounds studied for skin regeneration, cellular longevity, anti-inflammatory repair, telomere biology, and antioxidant defense.

GHK-Cu (Copper Peptide)

1–5 mg • SC / Topical • Daily to 3x weekly

Copper-binding tripeptide studied for skin regeneration, collagen synthesis, wound healing, and anti-inflammatory effects.

Protocol Parameter	Research Reference
Dosage (SC)	1–5 mg per administration
Dosage (Topical)	0.1–1% concentration in topical formulations
Frequency	Daily to 3x weekly (SC); daily topical in skin studies
Duration / Cycle	4–12 weeks
Timing	Evening preferred for circadian skin repair alignment
Route	SC injection, topical, intradermal
Reconstitution	Bacteriostatic water or sterile saline • 1–5 mg/mL

Research Notes

Collagen and elastin synthesis upregulation in fibroblast and skin models
Anti-inflammatory via TNF-alpha and IL-6 downregulation
DNA repair gene activation studied in aging cell models

🧪 Studied alongside BPC-157 and KPV in comprehensive repair protocols

KPV

0.1–1 mg/kg • SC / Oral • Daily

Alpha-MSH C-terminal tripeptide studied for anti-inflammatory, gut repair, and wound healing effects.

Protocol Parameter	Research Reference
Dosage (SC)	0.1–1 mg/kg per administration
Dosage (Oral)	Higher doses in GI inflammation models
Frequency	Once to twice daily
Duration / Cycle	2–8 weeks depending on inflammatory model
Route	SC injection, oral (GI studies), topical (wound models)
Reconstitution	Bacteriostatic water or sterile saline • 0.5–1 mg/mL

Research Notes

NF-κB pathway inhibition and cytokine downregulation in inflammatory models
Gut epithelial repair studied in colitis and IBD rodent models

🧪 Studied alongside BPC-157 and GHK-Cu in multi-peptide repair protocols

NAD+ (Nicotinamide Adenine Dinucleotide)

250–1,000 mg • IV / SC / Oral • Daily to weekly

Essential coenzyme studied for mitochondrial function, DNA repair, sirtuin activation, and cellular energy metabolism.

Protocol Parameter	Research Reference
Dosage (IV)	250–1,000 mg per session
Dosage (SC)	25–100 mg per administration
Dosage (Oral precursors)	NMN: 250–1,000 mg/day; NR: 300–1,000 mg/day
Frequency (IV)	1–3x weekly; daily in acute repletion protocols
Frequency (SC / Oral)	Daily in most published studies
Duration / Cycle	4–12 weeks; ongoing in longevity research models
Route	IV infusion, SC injection, oral (via NMN/NR precursors)
Reconstitution	Sterile saline (IV); bacteriostatic water (SC) • per COA

Research Notes

Sirtuin (SIRT1–7) activation for epigenetic regulation and longevity pathways
PARP-1 activation for DNA repair in oxidative stress and aging models
Levels decline ~50% between ages 40–60 in human tissue studies

🧪 Studied alongside MOTS-C and 5-Amino-1MQ for mitochondrial health protocols

SS-31 (Elamipretide)

0.5–5 mg/kg • SC / IV • Daily to 3x weekly

Mitochondria-targeted tetrapeptide studied for cardioprotection, mitochondrial membrane stabilization, and oxidative stress reduction.

Protocol Parameter	Research Reference
Dosage (SC)	0.5–5 mg/kg per administration in rodent studies
Dosage (IV)	0.05–0.25 mg/kg in cardiac and renal models
Frequency	Daily to 3x weekly depending on study model
Duration / Cycle	2–12 weeks; acute single-dose studies also published
Timing	Pre-ischemia or pre-exercise in cardioprotection studies
Route	SC injection, IV infusion
Reconstitution	Sterile saline or bacteriostatic water • 1–5 mg/mL

Research Notes

Selectively targets inner mitochondrial membrane via cardiolipin binding
ATP production restoration studied in aged and ischemic tissue models
ROS reduction in cardiac, renal, and skeletal muscle models
Mitochondrial cristae structure preservation in aging and heart failure models

🧪 Studied alongside NAD+ and MOTS-C in mitochondrial health protocols

Glutathione 1500mg

600–1,500 mg • IV / SC / Nebulized • 1–3x weekly

Master endogenous antioxidant studied for oxidative stress reduction, immune modulation, detoxification, and skin brightening.

Protocol Parameter	Research Reference
Dosage (IV)	600–1,500 mg per session
Dosage (SC)	200–600 mg per administration
Dosage (Nebulized)	600 mg in pulmonary oxidative stress models
Frequency	1–3x weekly (IV); daily to 3x weekly (SC)
Duration / Cycle	4–12 weeks; ongoing in chronic oxidative stress models
Timing	IV sessions: 30–60 min infusion duration
Route	IV infusion, SC injection, nebulized (pulmonary studies)
Reconstitution	Sterile saline (IV); bacteriostatic water (SC) • use immediately after reconstitution

Research Notes

Tripeptide (Glu-Cys-Gly) — primary intracellular antioxidant and detoxification agent
Melanin synthesis inhibition via tyrosinase pathway in skin brightening research
Immune modulation via NK cell and T-cell activity enhancement
Oral bioavailability limited — IV and SC routes preferred for systemic delivery

🧪 Studied alongside NAD+ and GHK-Cu in anti-aging and antioxidant protocols

Epitalon (Epithalon)

5–10 mg • SC / IV • Daily (cycle-based)

Synthetic tetrapeptide studied for telomere elongation, telomerase activation, pineal gland regulation, and longevity in aging models.

Protocol Parameter	Research Reference
Dosage	5–10 mg per administration
Frequency	Once daily during active cycle
Duration / Cycle	10–20 day cycles; 2–4 cycles per year
Cycle Structure	10–20 days on → 4–6 months off → repeat
Timing	Evening preferred — melatonin and pineal regulation alignment
Route	SC injection, IV infusion
Reconstitution	Bacteriostatic water or sterile saline • 5–10 mg/mL

Research Notes

Telomerase activation and telomere elongation in human somatic cell models
Pineal gland peptide bioregulator — melatonin normalization in aged subjects
Lifespan extension studied in fruit fly and rodent aging models
Antioxidant enzyme (SOD, catalase) upregulation in aging cell studies

🧪 Studied alongside NAD+, SS-31, and GHK-Cu in longevity and anti-aging protocols

🧬 Tissue Repair Peptides▼

Peptides studied for cellular repair, wound healing, and musculoskeletal recovery in research models.

BPC-157

1–10 mcg/kg • SC / IP / Oral

Synthetic pentadecapeptide studied for GI protection, tendon repair, and angiogenesis.

Protocol Parameter	Research Reference
Dosage (Systemic)	1–10 mcg/kg per administration (SC or IP)
Dosage (Oral / GI)	10 mcg/kg in rodent GI models
Dosage (Local)	Higher concentrations in wound/tendon models
Frequency	Once daily; twice daily in acute injury models
Duration / Cycle	4–12 weeks; continuous in some chronic GI studies
Route	SC, IP, oral (GI studies), local injection
Reconstitution	Bacteriostatic water • 500–1,000 mcg/mL

Research Notes

Stable in gastric acid — studied orally in GI-focused research
Angiogenic, anti-inflammatory, and cytoprotective properties documented

🧪 Often stacked with TB-500 for synergistic tissue repair

TB-500 (Thymosin Beta-4 Fragment)

2–2.5 mg • SC

Thymosin Beta-4 fragment studied for actin regulation, cell migration, and tissue repair.

Protocol Parameter	Research Reference
Dosage	2–2.5 mg per administration; ~2 mg/kg weight-based
Frequency (Loading)	2x weekly for 4–6 weeks
Frequency (Maintenance)	1x weekly or bi-weekly
Duration / Cycle	6–12 weeks total
Route	SC injection
Reconstitution	Bacteriostatic water • 2 mg/mL

Research Notes

Actin-sequestering mechanism in cell migration and wound healing models
Anti-inflammatory and angiogenic properties documented

🧪 Commonly stacked with BPC-157

📈 GH Secretagogues▼

Peptides that stimulate GH release via GHRH or ghrelin receptor pathways, studied in metabolic and endocrine research.

Ipamorelin

100–300 mcg • SC • 2–3x daily

Selective GH secretagogue with clean GH pulse stimulation and minimal cortisol elevation.

Protocol Parameter	Research Reference
Dosage	100–300 mcg per administration
Frequency	2–3x daily; pre-sleep dosing studied for GH pulsatility
Duration / Cycle	8–12 weeks on, 4 weeks off
Timing	Fasted state or pre-sleep preferred
Route	SC injection
Reconstitution	Bacteriostatic water • 1,000 mcg/mL

Research Notes

Highly selective — minimal cortisol or prolactin elevation
Most selective GHRP in comparative receptor studies

🧪 Stack with CJC-1295 for synergistic GH pulse amplification

CJC-1295

100–300 mcg (no DAC) • 1–2 mg (DAC)

GHRH analogue studied for sustained GH and IGF-1 elevation. Available with or without DAC.

Protocol Parameter	Research Reference
Dosage (No DAC)	100–300 mcg per administration
Dosage (With DAC)	1–2 mg per administration
Frequency (No DAC)	2–3x daily
Frequency (With DAC)	1–2x weekly (half-life ~6–8 days)
Duration / Cycle	8–12 weeks on, 4 weeks off
Route	SC injection
Reconstitution	Bacteriostatic water • 1–2 mg/mL

Research Notes

DAC variant binds albumin — extended half-life in animal studies
Non-DAC produces more physiological pulsatile GH release

🧪 Co-administer with Ipamorelin or GHRP-2

GHRP-2

100–300 mcg • SC • 2–3x daily

Potent GH secretagogue via ghrelin receptor agonism. Studied in metabolic and endocrine models.

Protocol Parameter	Research Reference
Dosage	100–300 mcg per administration
Frequency	2–3x daily; fasted state preferred
Duration / Cycle	4–12 weeks
Timing	Fasted or pre-sleep for maximal GH pulse
Route	SC injection
Reconstitution	Bacteriostatic water • 1,000 mcg/mL

Research Notes

May elevate cortisol and prolactin at higher doses vs. Ipamorelin
Appetite stimulation via ghrelin receptor agonism in rodent models

🧪 Stack with CJC-1295 for amplified GH pulse

Tesamorelin

1–2 mg • SC • Once daily

Stabilized GHRH analogue studied for visceral fat reduction and GH/IGF-1 elevation in metabolic models.

Protocol Parameter	Research Reference
Dosage	1–2 mg per administration
Frequency	Once daily; pre-sleep or morning in metabolic studies
Duration / Cycle	12–26 weeks; off periods recommended
Timing	Pre-sleep preferred to align with natural GH pulsatility
Route	SC injection
Reconstitution	Bacteriostatic water • 1–2 mg/mL

Research Notes

Studied for visceral adiposity reduction in HIV-associated lipodystrophy models
More stable than native GHRH due to trans-3-hexenoic acid modification

🧪 Studied with Ipamorelin for enhanced GH axis stimulation

💉 GLP-1 / Metabolic Receptor Agonists▼

Incretin-based and amylin-related peptides studied for glucose regulation, appetite suppression, and body composition in metabolic research models.

Tirzepatide

2.5–15 mg • SC • Once weekly

Dual GIP/GLP-1 receptor agonist studied for glucose regulation, appetite suppression, and weight reduction.

Protocol Parameter	Research Reference
Dosage (Starting)	2.5 mg per administration
Dosage (Maintenance)	5–15 mg; titrated every 4 weeks
Frequency	Once weekly; consistent day of week
Duration / Cycle	12–72 weeks in published metabolic and obesity studies
Titration Schedule	2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg (every 4 weeks)
Route	SC injection
Reconstitution	Per COA; bacteriostatic water if lyophilized

Research Notes

Dual GIPR + GLP-1R agonist — differentiated from GLP-1 mono-agonists
Slow titration minimizes GI side effects in research subjects

🧪 Studied alongside Cagrilintide in combination metabolic protocols

Retatrutide

1–12 mg • SC • Once weekly

Triple GIP/GLP-1/Glucagon receptor agonist studied for weight reduction and metabolic regulation.

Protocol Parameter	Research Reference
Dosage (Starting)	1–2 mg per administration
Dosage (Maintenance)	4–12 mg; titrated every 4 weeks
Frequency	Once weekly
Duration / Cycle	24–48 weeks in published Phase 2 studies
Route	SC injection
Reconstitution	Per COA; bacteriostatic water if lyophilized

Research Notes

Triple agonist: GIPR + GLP-1R + Glucagon receptor
Among the most potent weight reduction peptides in Phase 2 trials to date

🧪 Next-generation alternative to dual GIP/GLP-1 agonists

Cagrilintide

0.16–4.5 mg • SC • Once weekly

Long-acting amylin analogue studied for appetite regulation, gastric emptying, and weight reduction.

Protocol Parameter	Research Reference
Dosage (Starting)	0.16–0.3 mg per administration
Dosage (Maintenance)	2.4–4.5 mg; titrated every 4 weeks
Frequency	Once weekly
Duration / Cycle	20–32 weeks in published obesity studies
Route	SC injection
Reconstitution	Per COA; bacteriostatic water if lyophilized

Research Notes

Amylin receptor agonist — complementary to GLP-1 receptor agonists
Combination with semaglutide (CagriSema) studied for additive weight reduction

🧪 Studied with Tirzepatide and semaglutide in metabolic research

🧠 Cognitive & Neuroprotective Peptides▼

Peptides studied for neuroprotection, cognitive enhancement, and anxiolytic effects in CNS research models.

Semax

100–900 mcg • Intranasal / SC • 1–2x daily

ACTH analogue studied for neuroprotection, BDNF upregulation, and cognitive enhancement.

Protocol Parameter	Research Reference
Dosage (Intranasal)	100–900 mcg per administration
Dosage (SC)	100–300 mcg per administration
Frequency	1–2x daily
Duration / Cycle	2–4 weeks on, 1–2 weeks off
Timing	Morning preferred
Route	Intranasal (preferred), SC
Reconstitution	Sterile saline or bacteriostatic water

Research Notes

BDNF and NGF upregulation in CNS injury models
Short cycling recommended to prevent receptor adaptation

🧪 Often studied alongside Selank for combined cognitive + anxiolytic effects

Selank

250–3,000 mcg • Intranasal / SC • 1–2x daily

Tuftsin analogue studied for anxiolytic, nootropic, and immunomodulatory effects without sedation.

Protocol Parameter	Research Reference
Dosage (Intranasal)	250–3,000 mcg per administration
Dosage (SC)	250–500 mcg per administration
Frequency	1–2x daily
Duration / Cycle	2–4 weeks on, 1–2 weeks off
Route	Intranasal (preferred), SC
Reconstitution	Sterile saline or bacteriostatic water

Research Notes

Non-sedating anxiolytic profile in comparative rodent studies
IL-6 modulation and enkephalin system interaction studied

🧪 Studied with Semax for combined cognitive and anxiolytic protocols

🔥 Metabolic Peptides▼

Peptides studied for fat metabolism, mitochondrial function, insulin sensitivity, and body composition in metabolic research models.

AOD-9604 (Fragment 176-191)

250–500 mcg • SC • 1–2x daily

hGH fragment studied for lipolytic activity without affecting IGF-1 or blood glucose.

Protocol Parameter	Research Reference
Dosage	250–500 mcg per administration
Frequency	1–2x daily; fasted state preferred
Duration / Cycle	8–12 weeks
Timing	Morning fasted for maximal lipolytic effect
Route	SC injection
Reconstitution	Bacteriostatic water • 500 mcg/mL

Research Notes

Does not affect blood glucose or IGF-1 — key differentiator from full hGH
Beta-3 adrenergic receptor-mediated lipolysis mechanism studied

🧪 Studied with GHRP peptides in body composition research

5-Amino-1MQ

50–100 mg • Oral • Once daily

NNMT inhibitor studied for fat cell reduction, metabolic rate enhancement, and NAD+ pathway activation.

Protocol Parameter	Research Reference
Dosage	50–100 mg per administration
Frequency	Once daily
Duration / Cycle	4–12 weeks; cycling recommended
Timing	Morning in circadian metabolic models
Route	Oral (primary); SC in some models
Reconstitution	DMSO or PEG-400 for SC; oral capsule for oral studies

Research Notes

NNMT inhibitor — increases intracellular SAM and NAD+ precursors
Adipocyte size reduction and thermogenesis upregulation in obesity models

🧪 Studied alongside NAD+ for complementary metabolic pathway activation

MOTS-C

5–10 mg/kg • SC / IP • Daily to 3x weekly

Mitochondria-derived peptide studied for metabolic regulation, insulin sensitivity, and exercise mimicry.

Protocol Parameter	Research Reference
Dosage	5–10 mg/kg per administration
Frequency	Daily to 3x weekly depending on study endpoint
Duration / Cycle	4–8 weeks
Timing	Pre-exercise or morning in metabolic studies
Route	SC or IP injection
Reconstitution	Bacteriostatic water or sterile saline • per COA

Research Notes

Encoded in mitochondrial 12S rRNA — unique mitochondria-derived peptide
AMPK activation, glucose uptake, and insulin sensitization in skeletal muscle models
Levels decline with age — studied in longevity and metabolic aging research

🧪 Studied alongside NAD+ and 5-Amino-1MQ in mitochondrial health research

🌟 Melanocortin Peptides▼

Peptides interacting with melanocortin receptors, studied for pigmentation, sexual function, and appetite regulation.

Melanotan II

0.5–2 mg • SC • Daily (loading)

Cyclic alpha-MSH analogue studied for melanogenesis, sexual function, and appetite suppression.

Protocol Parameter	Research Reference
Dosage	0.5–2 mg per administration
Frequency (Loading)	Daily for 2–4 weeks
Frequency (Maintenance)	2–3x weekly or as-needed
Duration / Cycle	2–4 weeks loading; maintenance varies
Route	SC injection
Reconstitution	Bacteriostatic water • 1–2 mg/mL

Research Notes

Non-selective MC receptor agonist (MC1R, MC3R, MC4R)
UV-independent melanogenesis in skin pigmentation research

🧪 Broader receptor profile vs. PT-141 in comparative MC receptor studies

PT-141 (Bremelanotide)

0.5–2 mg • SC • As-needed

MC3R/MC4R agonist studied for sexual arousal and erectile function via CNS-mediated mechanism.

Protocol Parameter	Research Reference
Dosage	0.5–2 mg per administration
Frequency	As-needed; not for daily chronic use
Minimum Interval	72 hours between administrations
Duration / Cycle	Short-term / acute study designs
Route	SC injection
Reconstitution	Bacteriostatic water • 1 mg/mL

Research Notes

More selective than Melanotan II — primarily MC3R/MC4R
CNS-mediated mechanism in arousal and erectile function models

🧪 More targeted alternative to Melanotan II in sexual function research

💠 Peptives Proprietary Blends▼

Peptives-formulated research blends. Contact Peptives for full COA and formulation data.

Klow80

Per Peptives COA • For Research Use Only

Peptives proprietary research blend. Refer to product COA and formulation sheet for full protocol specifications.

Protocol Parameter	Research Reference
Dosage	Per Peptives product COA and formulation specification
Frequency	Per Peptives protocol sheet included with product
Duration / Cycle	Per Peptives research protocol documentation
Route	Per Peptives formulation specification
Reconstitution	Per Peptives COA • Bacteriostatic water unless otherwise specified
Storage	-20°C lyophilized; 4°C reconstituted (up to 7 days)

Research Notes

Proprietary Peptives formulation — full ingredient and ratio data on COA
Purity verified at ≥98% HPLC per Peptives quality standards

📋 Request the full Klow80 COA and protocol sheet from Peptives for complete research specifications.

Glow70

Per Peptives COA • For Research Use Only

Peptives proprietary research blend. Refer to product COA and formulation sheet for full protocol specifications.

Protocol Parameter	Research Reference
Dosage	Per Peptives product COA and formulation specification
Frequency	Per Peptives protocol sheet included with product
Duration / Cycle	Per Peptives research protocol documentation
Route	Per Peptives formulation specification
Reconstitution	Per Peptives COA • Bacteriostatic water unless otherwise specified
Storage	-20°C lyophilized; 4°C reconstituted (up to 7 days)

Research Notes

Proprietary Peptives formulation — full ingredient and ratio data on COA
Purity verified at ≥98% HPLC per Peptives quality standards

📋 Request the full Glow70 COA and protocol sheet from Peptives for complete research specifications.

Disclaimer: All content is for informational and research reference purposes only. Peptives products are sold exclusively for in vitro and laboratory research use. Not intended for human or veterinary use, diagnosis, or treatment. Researchers are responsible for compliance with all applicable institutional, local, and national regulations.